In vitro determination of the immunosuppressive effect, internalization, and release mechanism of squalene-gusperimus nanoparticles for managing inflammatory responses

References

• Kälsch AI, Schmitt WH, Breedijk A, et al. In vivo effects of cyclic administration of 15-deoxyspergualin on leucocyte function in patients with Wegener's granulomatosis. Clin Exp Immunol. 2006;146(3):455–462.
   PubMed Web of Science ®Google Scholar
• Navarro Chica CE, de Haan BJ, Faas MM, et al. Design and characterization of Squalene-Gusperimus nanoparticles for modulation of innate immunity. Int J Pharm. 2020;590:119893.
   PubMed Web of Science ®Google Scholar
• Perenyei M, Jayne DRW, Floßmann O. Gusperimus: Immunological mechanism and clinical applications. Rheumatology. 2014;53(10):1732–1741.
   PubMed Web of Science ®Google Scholar
• Kaufman DB, Gores PF, Kelley S, et al. 15-Deoxyspergualin: immunotherapy in solid organ and cellular transplantation. Transplant. Rev. 1996;10(3):160–174.
   Google Scholar
• Gusperimus|C17H37N7O3 – PubChem (n.d.) [cited 2019 Oct 23]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/55362#section=Experimental-Properties
   Google Scholar
• Fujii H, Takada T, Nemoto K, et al. In vitro immunosuppressive properties of spergualins to murine T cell response. J Antibiot. 1989;42(5):788–794.
   PubMed Web of Science ®Google Scholar
• Yesylevskyy SO, Ramseyer C, Savenko M, et al. Low-density lipoproteins and human serum albumin as carriers of squalenoylated drugs: insights from molecular simulations. Mol Pharm. 2018;15(2):585–591.
   PubMed Web of Science ®Google Scholar
• Sobot D, Mura S, Rouquette M, et al. Circulating lipoproteins: a trojan horse guiding squalenoylated drugs to LDL-accumulating cancer cells. Mol Ther. 2017;25(7):1596–1605.
   PubMed Web of Science ®Google Scholar
• Brusini R, Dormont F, Cailleau C, et al. Squalene-based nanoparticles for the targeting of atherosclerotic lesions. Int J Pharm. 2020;581:119282.
   PubMed Web of Science ®Google Scholar
• Sobot D, Mura S, Yesylevskyy SO, et al. Conjugation of squalene to gemcitabine as unique approach exploiting endogenous lipoproteins for drug delivery. Nat Commun. 2017;8:15678–15679.
   PubMed Web of Science ®Google Scholar
• Rouquette M, Lepetre-Mouelhi S, Dufrançais O, et al. Squalene-adenosine nanoparticles: ligands of adenosine receptors or adenosine prodrug? J Pharmacol Exp Ther. 2019;369(1):144–151.
   PubMed Web of Science ®Google Scholar
• Feng J, Lepetre-Mouelhi S, Couvreur P. Design, preparation and characterization of modular squalene-based nanosystems for controlled drug release. Curr Top Med Chem. 2017;17:2849–2865.
   Web of Science ®Google Scholar
• Kerr PG, Ntkolic-Paterson DJ, Lan HY, et al. Deoxyspergualin suppresses local macrophage proliferation in rat renal allograft rejection. Transplantation. 1994;58:596–601.
   PubMed Web of Science ®Google Scholar
• Barreras-Urbina CG, Ramírez-Wong B, López-Ahumada GA, et al. Nano- and micro-particles by nanoprecipitation: possible application in the food and agricultural industries. Int J Food Prop. 2016;19(9):1912–1923.
   Web of Science ®Google Scholar
• Anderson JM, Rodriguez A, Chang DT. Foreign body reaction to biomaterials. Semin Immunol. 2008;20(2):86–100.
   PubMed Web of Science ®Google Scholar
• Asokan A, Cho MJ. Exploitation of intracellular pH gradients in the cellular delivery of macromolecules. J Pharm Sci. 2002;91(4):903–913.
   PubMed Web of Science ®Google Scholar
• Fujiwara N, Kobayashi K. Macrophages in inflammation. Curr Drug Targets Inflamm Allergy. 2005;4(3):281–286.
   PubMedGoogle Scholar
• Andersen MH, Schrama D, Thor Straten P, et al. Cytotoxic T cells. J Invest Dermatol. 2006;126(1):32–41.
   PubMed Web of Science ®Google Scholar
• Rautio J, Kumpulainen H, Heimbach T, et al. Prodrugs: design and clinical applications. Nat Rev Drug Discov. 2008;7(3):255–270.
   PubMed Web of Science ®Google Scholar
• Kerr PG, Atkins RC. Deoxyspergualin inhibits cytotoxic T lymphocytes but not NK or LAK cells. Immunol Cell Biol. 1991;69(3):177–183.
   PubMed Web of Science ®Google Scholar
• Yuan J, Cai T, Zheng X, et al. Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling. Protein Cell. 2021;12(4):240–260.
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Brown MS, Anderson RG, et al. Receptor-mediated endocytosis: concepts emerging from the LDL receptor system. Annu Rev Cell Biol. 1985;1:1–39.
   PubMedGoogle Scholar
• McMahon HT, Boucrot E. Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol. 2011;12(8):517–533.
   PubMed Web of Science ®Google Scholar
• Kzhyshkowska J, Neyen C, Gordon S. Role of macrophage scavenger receptors in atherosclerosis. Immunobiology. 2012;217(5):492–502.
   PubMed Web of Science ®Google Scholar
• Slobbe L. Drugs that act on the immune system: immunosuppressive and immunostimulatory drugs. 1st ed. Amsterdam, The Netherlands: Elsevier B.V.; 2012.
   Google Scholar